Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Quantum Genomics [ALQGC] ::.

Quantum Genomics is a French-based company dedicated to the development of drugs for cardiovascular diseases. Its lead program, QGC-001 is being tested in a Phase IIa clinical trial to study its efficacy in resistant hypertension. QGC-001, a first-in class drug, inhibits brain aminopeptidase A, whose role in hypertension has been demonstrated in animal models. QGC-001 could provide a therapeutic solution for resistant hypertension that affects 10-15% of all hypertensive patients.

The coverage was initiated November 4th, 2014

Our target price for Quantum Genomics as of Sept 25th, 2017, is €11.50/ share